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Abstract 
Ebola hemorrhagic fever (EHF) was first reported in 1976 with two concurrent outbreaks of acute viral hemor-
rhagic fever centered in Yambuku (near the Ebola river), Democratic Republic of Congo, and in Nzara, Sudan. The 
current outbreak of the Ebola virus was started by reporting the first case in March 2014 in the forest regions of 
southeastern Guinea. Due to infection rates raising over 13,000% within a 6-month period, Ebola is now consid-
ered as a global public health emergency and on August 8th, 2014 the World Health Organization (WHO) declared 
the epidemic to be a Public Health Emergency of International Concern. With more than 5000 involved cases and 
nearly 3000 deaths, this event has turned into the largest and most dangerous Ebola virus outbreak in the world. 
Based on the above-mentioned, the present article aimed to review the virologic characteristics, transmission, 
clinical manifestation, diagnosis, treatment, and prevention of Ebola virus disease. 
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Introduction: 
bola hemorrhagic fever (EHF) was first reported 
in 1976 with two concurrent outbreaks of acute 
viral hemorrhagic fever centered in Yambuku 
(near the Ebola River), Democratic Republic of Congo, 
and also in Nzara, Sudan. There have been almost 20 
other outbreaks that involve nearly 2500 cases hap-
pened before 2014. With the exception of a single case 
identified in the Republic of Ivory Coast in the 1990s, all 
of them were reported in sub-Saharan Africa involving 
the Sudan, Gabon, Uganda, and Democratic Republic of 
Congo (1). But the current outbreak (2014), which is 
the largest one ever documented, is the first recorded 
outbreak of Ebola in West Africa (2). The previous larg-
est outbreaks of Ebola virus was identified in Uganda in 
2000–2001, which was caused by Sudan Ebola virus 
(SUDV) subtype. This outbreak resulted in nearly 400 
cases, 216 of which were laboratory confirmed and had 
53% overall case-fatality rate (3). The 25th known out-
break of the Ebola Virus was started by reporting the 
first case in March 2014 in the forest regions of south-
eastern Guinea. Its infection rates reached 13,000% 
within a 6-month period. In August 8, 2014 the World 
Health Organization (WHO) declared the epidemic to be 
a Public Health Emergency of International Concern (2, 
4). Thereafter, Ebola virus has spread through the West 
Africa and appeared in Senegal, Sierra Leone, Liberia, 
Nigeria, and now it has been reported in Spain and 
United States of America, too. With more than 5000 
involved cases and nearly 3000 deaths, this event has 
turned into the largest and most dangerous Ebola virus 
outbreak all around the world (5). Based on the above-
mentioned, the present article aimed to review the 
virologic characteristics, transmission, clinical manifes-
tation, diagnosis, treatment, and prevention of Ebola 
virus disease. 
Virologic characteristics 
Ebola virus is a lipid-enveloped ribonucleic acid (RNA) 
virus, which belongs to the Filoviridae family and 
known since 1976. It consists of five different sub-types 
and Ebola virus Zaire sub-type (ZEBOV) was the first 
one to be recognized in the Democratic Republic of 
Congo. The current Ebola virus has 97% homology with 
ZEBOV (6, 7). Other subtypes include Bundibugyo 
(BDBV), SUDV, Côte d'Ivoire or Tai Forest (TAFV) and 
Reston Ebola viruses (RESTV). Ebola hemorrhagic fever 
(EHF), caused by ZEBOV, has the highest fatality (57%–
90%), followed by SUDV (41%–65%) and BDBV (40%) 
and these 3 sub-types are responsible for the large out-
breaks that recently occurred in Africa. However to 
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date, RESTV infection has been observed in animals in 
Asia and as an asymptomatic disease in humans, while 
TAFV has only been identified in 2 human cases, both of 
which were nonfatal (4, 8, 9). 
Transmission  
Some authors claimed that a 44-year-old man suffering 
from malaria was the first identified fatal case of EHF 
who was infected using a contaminated needle for ad-
ministration of parenteral chloroquine in the Democrat-
ic Republic of Congo (previously named Zaire) in 1976 
(1). On the other hand, some researches indicated that 
the first person became infected through contact with 
an infected animal (4). Fruit bats that live in Guinea and 
its neighboring countries are considered as the natural 
hosts of Ebola viruses, and other mammals serve as 
accidental hosts. This virus has been implicated as one 
of the major causes of decreasing African chimpanzee 
and gorilla populations in recent decades (1, 10, 11). 
Ebola is one of the zoonotic viruses that can lead to a 
highly fatal disease in human beings. Humans are also 
one of the accidental hosts and can be infected through 
close contact with blood and bodily fluids of another 
infected case (including humans and animals), either by 
direct contact or indirectly from a contaminated envi-
ronment. It seems that mosquitoes and other insects do 
not play a role in virus transmission and also it is not 
spread through the air (1, 4, 10). Ebola virus has high 
transmissibility and virulence and less than 10 viral 
particles are enough for becoming infected. The incuba-
tion period range is 2-21 days (average 5-6). Fortunate-
ly, the disease is not transmissible until the patient be-
comes symptomatic, but it continues to be contagious, 
even postmortem (2, 12). Family and healthcare pro-
viders caring for Ebola patients are at the highest risk 
for becoming infected because of their possible contact 
with contaminated blood or body fluids. So the virus 
can easily spread if reasonable preventive precautions 
are not taken (4). 
Clinical Manifestation 
The patients with suggestive symptoms, including un-
explained hemorrhage and risk factors within the last 3 
weeks such as contact with suspected or confirmed EHF 
cases, or travel to an endemic area should be evaluated 
for EHF (2). EHF is a fatal disease (mortality rate 50%-
70%) that can occur 2-21 days after exposure to the 
virus. The initial clinical presentation is non-specific.  
Early clinical symptoms of EHF include abrupt onset of 
fever, fatigue, myalgia and headache followed by pro-
gressive gastrointestinal symptoms such as anorexia, 
nausea, and abdominal discomfort accompanied by 
vomiting and diarrhea within 1-2 days. This process can 
lead to intravascular volume depletion and also pro-
found electrolyte disorders, hypoperfusion, shock, and 
multi-organ failure (acute respiratory, liver, and renal 
failure) within a few days. The “hemorrhage” in the 
phrase “Ebola hemorrhagic fever” is a late manifesta-
tion, which usually occurs as gastrointestinal bleeding, 
conjunctival hemorrhage, epistaxis, and hemorrhagic 
rash. Some others believe that these symptoms occur 
only in a minority of patients, that is why they use “Ebo-
la virus disease” instead (1, 2, 5, 9, 10, 12-16). Complete 
blood count usually shows leucopenia and thrombocy-
topenia, but hemoglobin levels almost never decrease 
significantly. Intravascular volume depletion and 
hypoperfusion are manifested by metabolic lactic aci-
dosis and renal insufficiency. Massive diarrhea associ-
ates with profound hypokalemia and hematogenous 
spread of virus to the liver and spleen and leads to 
hepatocellular injury marked by elevated liver enzymes 
(2, 5, 12-14). Analysis of coagulation profile shows in-
creased prothrombin and partial thromboplastin times 
(PT and PTT) accompanied by detection of fibrin deg-
radation products in the occurrence of disseminated 
intravascular coagulation (DIC) (6).   
Diagnosis  
Apart from Ebola virus, there are other types of viruses 
that can cause hemorrhagic fever, including Crimean-
Congo hemorrhagic fever virus, Marburg virus, Lassa 
virus, and emerging ones such as Lujo virus. These vi-
ruses have particular public health importance because 
of their spreading ability to healthcare workers, difficul-
ties in their rapid recognition, lack of effective specific 
therapeutics, and  high fatality rate (10). Definite diag-
nosis of a clinically suspected case of Ebola virus infec-
tion requires laboratory confirmation. In EHF, viremia 
develops after the fever and takes up to 3 days to con-
firm the diagnosis by proper laboratory evaluation. It is 
necessary to collect serum, plasma, or whole blood 
samples of at least 4 milliliters, and take them to the 
appropriate health department, refrigerated or on ice, 
for further testing. Early diagnosis is confirmed via de-
tecting viral antigens by using polymerase chain reac-
tion (PCR) or enzyme-linked immunosorbent assay 
(ELISA) on the blood sample. Later in the disease 
course, antibodies against the virus such as Immuno-
globulin M (IgM) and Immunoglobulin G (IgG) can also 
be detected. If the test results were positive, local and 
state health departments should be notified immediate-
ly. However, because of the extreme biohazard risk, 
using antigen- or antibody-based assays or PCR testing 
should be performed in level 4 biosafety laboratories, 
which is more possible in developed countries where 
such laboratories are available (1, 2, 17). Centers of 
Disease Control and Prevention (CDC) have performed 
standardized enzyme-linked immunosorbent assay 
(ELISA) for detection of Ebola virus specific antibodies. 
This test has high sensitivity and can be used for detect-
ing antibodies in human beings even 10 years after ex-
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There is no specific antiviral agent or vaccine against 
Ebola viruses. Therefore, supportive care is the most 
important aspect of its management. Aggressive pre-
vention of intravascular volume depletion is critical to 
avoid life-threatening complications by using proper 
fluid therapy, oxygen therapy, correcting profound elec-
trolyte abnormalities, and preventing the complications 
of shock such as acid–base derangements. Treatment of 
other infections, if they occur, and close monitoring of 
vital signs and regular biochemical and blood gas 
checks should be done. These proceedings are consid-
ered as the foundation of critical care medicine and 
should be applied to both resource-rich and resource-
constrained settings. With improving supportive cares, 
EHF outcomes may also improve. Symptom control 
with taking narcotics and benzodiazepines were often 
reported as the end-of-life therapy in some patients (2, 
5, 14). A variety of chemotherapeutic agents have been 
tested for different stages of development. Recombi-
nant human activated protein C and recombinant nema-
tode anticoagulant protein C2 are also among them. One 
drug identified as ZMAPP, has been used on several pa-
tients, however it remains unclear if it is effective or 
not. Therefore, no Food and Drug Administration (FDA) 
approved agent exists against Ebola (4, 6, 18-23). Fig-
ure 1 shows the latest CDC algorithm regarding emer-
gency department evaluation and management for pos-
sible Ebola infected patients. 
Prevention 
The current outbreak of EHF highlighted the im-
portance of prevention strategies. Health care workers 
have represented a considerable proportion of all in-
fected cases. So educating and training the medical staff 
on universal precautions, risk assessment, and use of 
personal protective equipment is crucial. Patients ini-
tially identified as having a possible viral hemorrhagic 
fever should be isolated until the results of their specific 
diagnosis are obtained from reference laboratories. It is 
important not to delay diagnosis and treatment of more 
common diseases, such as malaria or typhoid, during 
this period. Follow-up of contact cases is essential for 
infection containment in case the patient tests are posi-
tive. Specially equipped ambulances and trained staff 
should be prepared to do the transferring when needed 
(1, 10, 24). Early diagnosis and rapid laboratory con-
firmation along with isolation of patients and following 
their contacts, as well as access to protective equipment 
and environmental decontamination are the mainstay 
of prevention. 
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Figure 1: Shows the latest CDC algorithm regarding emergency department evaluation and management for possible Ebola in-
fected patients. 
